Ингаляционные глюкокортикостероиды при обструктивных болезнях легких

Побочные эффекты ИКС
   Все побочные эффекты, связанные с приемом ИКС, можно разделить на местные и системные. Системные эффекты развиваются вследствие системной абсорбции, а местные – в месте депозиции препаратов (см. табл. 5 и 6).

www.consilium-medicum.com /Том 3/N 3 (2001).

Литература
1. Barnes PJ, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157: S1-S53.
2. Barnes PJ, Godfrey S. Asthma therapy. Martin Dunitz Ltd, London 1998: 1-150.
3. British Thoracic Society. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 (Suppl 1): S1-S21.
4. Barnes NC, Hallett C, Harris TAJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92: 95-104.
5. Lipworth BJ. Targets for inhaled drugs. Respir Med 2000; 94 (Suppl.D): S13-S16.
6. Dempsey OJ, Wilson AM, Coutie WJR, Lipworth BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116: 935-40.
7. Vecchiet L, Pieralisi G, Ambrosi L, Di Lorenzo L, Cantini L. Inhaled beclomethasone dipropionate administered through a new spacer device: a controlled clinical study. Adv Ther 1996; 13: 335-46.
8. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998; 11: 113-25.
9. British Thoracic and Tuberculosis Association. Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 2 (7933): 469-73.
10. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta2 -agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-92.
11. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding SM. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103: 267-75.
12. Broder I, Tarlo SM, Davies GM, Thomas P, Leznoff A, Sturgess J, Baumal R, Mintz S, Corey PN Safety and efficacy of long-term treatment with inhaled beclomethasone dipropionate in steroid-dependent asthma. CMAJ 1987; 136: 129-135.
13. Nelson HS, Bernstein L, Fink J, Edwards T, Spector SL, Storms WW, Tashkin DP. for the Pulmicort Turbuhaler Study Group. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler. A double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Chest 1998; 113: 1264-71.
14. Higgenbottam TW, Clark RA, Luksza AR, Morice AH, Bateman NT, Matthews AW, Petrie G.R., Taylor M.D., Richardson P.D.I. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur.J.Clin.Res. 1994; 5: 1-10.
15. O’Byrne PM. Inhaled corticosteroid therapy in newly detected mild asthma. Drugs 1999; 58 (Suppl.4): 17-24.
16. O’Byrne PM, Cuddy L, Taylor DW, Birch S, Morris J. Syrotuik J. Efficacy and benefit of inhaled corticosteroid therapy in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3: 169-75.
17. Serloos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-34.
18. Суточникова О.А., Самсонова М.В., Черняк А.В., Черняев А.Л. Ингаляционная глюкокортикостероидная терапия больных бронхиальной астмой легкого течения. Влияние на воспаление и гиперреактивность. Пульмонология 1996; 4: 21-8.
19. Суточникова О.А., Самсонова М.В., Черняк А.В., Черняев А.Л. Ингаляционная глюкокортикостероидная терапия больных бронхиальной астмой легкого течения. Влияние на воспаление и гиперреактивность. Пульмонология 1996; 4: 21-8.
20. van der Molen T, Meyboom-de Jong B, Mulder HH, Postman DS. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. Am J Respir Crit Care Med 1998; 158: 121-5.
21. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma challenges and opportunities. J Asthma 1998; 35: 455-72.
22. Edsbacker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58(Suppl.4): 7- 16.
23. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma. Drugs 1999; 58 (Suppl.4): 25-33.
24. Nathan RA, Li JT, Finn A, Jones R, Payne JE, Wolford JP, Harding SM. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118: 296-302.
25. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-24.
26. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-11.
27. Devoy MAB, Fuller RW, Palmer JBD. Are there any detrimental effects of the use of inhaled long-acting beta2 -agonists in the treatment of asthma? Chest 1995; 107: 1116-24.
28. Цой А.Н., Шор О.А., Гафуров М.С. Эффективность глюкокортикостероидов при различном режиме дозирования и в комбинации с препаратами теофиллина у больных бронхиальной астмой. Тер. арх. 1997; 7 (3): 27-30.
29. Evans DJ, Taylor DA, Zetterstorm O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-18.
30. Virchow J Chr, Hassall SM, Summerton L, Harris A. Improved asthma control over 6 weeks in patients on high dose corticosteroids. Eur Respir J 1997; 10 (Suppl.25): 437s
31. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of salmeterol and montelukast as second-line therapy in asthmatic patients receiving inhaled corticosteroids. Eur Respir J 1999; 14 (Suppl.): p3486.
32. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-6.
33. British guidelines for the management of chronic obstructive pulmonary disease: the COPD Guidelines Group of Standarts of Care of the BTS. Thorax 1997; 52 (Suppl 5): S1-S28.
34. European Respiratory Society. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
35. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92: 537-48.
36. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-505.
37. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-8.
38. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-53.
39. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit Med J 2000; 320: 1297-303.
41. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
42. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long-term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta analysis. Thorax 1999; 54: 7-14.
43. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-80.
44. Renkema TE, Schouten JP, Koeter GH, et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-62.
45. van Schayck CP. Is lung function really a good parameter in evaluating the long-term effects of inhaled corticosteroids in COPD? Eur Respir J 2000; 15: 238-9.
46. Mapp CE. Inhaled glucocorticoids in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1890-1.
47. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313-7.
48. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-75.
49. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
50. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93: 967-76.